TimesSquare Capital Management, an equity investment management company, released its “U.S. Mid Cap Growth Strategy” first-quarter 2026 investor letter. A copy of the letter can be downloaded here. The Strategy fell 7.72% (net) in the quarter compared to -6.35% for the Russell Midcap Growth Index. In the first quarter, markets navigated geopolitical tensions and economic resilience alongside temporary global tariffs. High oil prices and supply chain disruptions followed U.S. and Israeli involvement in Iran, prompting a shift to safer assets and a reevaluation of supply chains and energy dependencies. Central banks maintained steady policies despite energy-driven inflation. In this environment, the Strategy remains focused on disciplined management teams with durable competitive advantages. Please review the Strategy’s top five holdings to gain insights into their key selections for 2026.
In its first-quarter 2026 investor letter, TimesSquare Capital U.S. Mid Cap Growth Strategy highlighted Repligen Corporation (NASDAQ:RGEN). Repligen Corporation (NASDAQ:RGEN) is a life science company that develops and distributes bioprocessing technologies and systems. On June 29, 2026, Repligen Corporation (NASDAQ:RGEN) closed at $137.00 per share. One-month return of Repligen Corporation (NASDAQ:RGEN) was 11.66%, and its shares gained 6.64% over the past 52 weeks. Repligen Corporation (NASDAQ:RGEN) has a market capitalization of $7.73 billion.
TimesSquare Capital U.S. Mid Cap Growth Strategy stated the following regarding Repligen Corporation (NASDAQ:RGEN) in its Q1 2026 investor letter:
“Our preferences among Health Care stocks are those companies providing novel therapies for unmet needs that command premium pricing, or specialized service providers. Repligen Corporation (NASDAQ:RGEN) is a global life sciences company offering bioprocessing technologies and solutions used in manufacturing biological drugs. Fourth quarter revenues and earnings were ahead of the consensus. Forward guidance factored in uncertainty regarding biopharmaceutical industry capital expenditures and the pace of FDA approvals causing the stock to sell off by -28%.”
Repligen Corporation (NASDAQ:RGEN) is not on our list of 40 Most Popular Stocks Among Hedge Funds Heading Into 2026. According to our database, 40 hedge fund portfolios held Repligen Corporation (NASDAQ:RGEN) at the end of the first quarter, compared to 43 in the previous quarter. In Q1 2026, Repligen Corporation (NASDAQ:RGEN) reported revenue of $194 million, marking an increase of 15% year over year. While we acknowledge the potential of Repligen Corporation (NASDAQ:RGEN) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
